Moreover, an anti-SEMA4D monoclonal antibody named VX15/2503 has been proved its broad-spectrum anti-tumor property in mouse and is entering clinical trials.[45] However, no evidence proves novel insight that SEMA4D can be utilized as a prognostic biomarker in diverse malignant tumors. Here, SEMA4D is linked to neoplasm.